WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
WuXi Biologics (WXXWY), a global Contract Research, Development, and Manufacturing Organization (CRDMO), has achieved a significant environmental milestone with the Science Based Targets initiative (SBTi) approving its near-term and net-zero greenhouse gas emissions reduction targets. The company commits to reaching net-zero emissions across its value chain by 2050, aligning with the 1.5°C global warming limitation pathway.
The comprehensive target matrix includes reducing absolute scope 1 and 2 GHG emissions by 58.8% by 2034 and scope 3 GHG emissions by 63.8% per kg of product from a 2024 base year. Long-term goals aim for a 90% reduction in both scope 1 and 2 emissions and scope 3 emissions by 2050. The company has received numerous sustainability recognitions, including an MSCI AAA Rating and EcoVadis Platinum Medal.
WuXi Biologics (WXXWY), organizzazione globale di Contract Research, Development and Manufacturing (CRDMO), ha raggiunto un importante traguardo ambientale: la Science Based Targets initiative (SBTi) ha approvato i suoi obiettivi di riduzione delle emissioni di gas serra a breve termine e per il net‑zero. L'azienda si impegna a conseguire il net‑zero lungo tutta la catena del valore entro il 2050, in linea con il percorso che limita il riscaldamento globale a 1,5°C.
Il piano dettagliato prevede la riduzione delle emissioni assolute scope 1 e 2 del 58,8% entro il 2034 e delle emissioni scope 3 del 63,8% per kg di prodotto rispetto all'anno base 2024. Gli obiettivi a lungo termine puntano a una riduzione del 90% sia per le scope 1 e 2 sia per le scope 3 entro il 2050. La società ha ricevuto numerosi riconoscimenti di sostenibilità, tra cui il rating MSCI AAA e la medaglia Platinum di EcoVadis.
WuXi Biologics (WXXWY), una organización global de Contract Research, Development, and Manufacturing (CRDMO), ha alcanzado un hito ambiental importante: la Science Based Targets initiative (SBTi) aprobó sus objetivos de reducción de emisiones de gases de efecto invernadero a corto plazo y de net‑zero. La compañía se compromete a lograr el net‑zero en toda su cadena de valor para 2050, alineándose con la trayectoria que limita el calentamiento global a 1,5°C.
La matriz de objetivos contempla reducir las emisiones absolutas de alcance 1 y 2 en un 58,8% para 2034 y las emisiones de alcance 3 en un 63,8% por kg de producto respecto al año base 2024. Las metas a largo plazo apuntan a una reducción del 90% tanto en alcance 1 y 2 como en alcance 3 para 2050. La compañía ha recibido múltiples reconocimientos en sostenibilidad, incluidos el rating MSCI AAA y la medalla Platinum de EcoVadis.
WuXi Biologics (WXXWY), 글로벌 계약 연구·개발·제조 조직(CRDMO), 이 중요한 환경적 이정표를 달성했습니다: Science Based Targets initiative(SBTi)가 단기 및 넷제로 온실가스 감축 목표를 승인했습니다. 회사는 2050년까지 가치사슬 전반에서 넷제로 달성하겠다고 약속하며, 지구 평균온도 상승을 1.5°C로 제한하는 경로에 발맞춥니다.
포괄적 목표 체계는 2024년 기준연도 대비 2034년까지 scope 1 및 2 절대 배출량을 58.8% 감축하고, 제품 kg당 scope 3 배출량을 63.8% 감축하는 것을 포함합니다. 장기 목표는 2050년까지 scope 1·2와 scope 3 모두에서 90% 감축을 지향합니다. 회사는 MSCI AAA 등급과 EcoVadis 플래티넘 메달 등 다수의 지속가능성 수상 실적을 보유하고 있습니다.
WuXi Biologics (WXXWY), organisation mondiale de Contract Research, Development and Manufacturing (CRDMO), a atteint un jalon environnemental majeur : la Science Based Targets initiative (SBTi) a approuvé ses objectifs de réduction des émissions de gaz à effet de serre à court terme et de neutralité carbone. L'entreprise s'engage à atteindre la neutralité carbone sur l'ensemble de sa chaîne de valeur d'ici 2050, conformément à la trajectoire visant à limiter le réchauffement à 1,5°C.
La matrice d'objectifs prévoit de réduire les émissions absolues scope 1 et 2 de 58,8% d'ici 2034 et les émissions scope 3 de 63,8% par kg de produit par rapport à l'année de référence 2024. Les objectifs à long terme visent une réduction de 90% des émissions scope 1 et 2 ainsi que scope 3 d'ici 2050. La société a obtenu de nombreuses distinctions en matière de durabilité, notamment la note MSCI AAA et la médaille Platinum d'EcoVadis.
WuXi Biologics (WXXWY), ein globales Contract Research, Development and Manufacturing Organization (CRDMO), hat einen wichtigen Umweltmeilenstein erreicht: Die Science Based Targets initiative (SBTi) hat seine kurzfristigen und Net‑Zero‑Treibhausgas‑Reduktionsziele genehmigt. Das Unternehmen verpflichtet sich, bis 2050 entlang der gesamten Wertschöpfungskette Net‑Zero‑Emissionen zu erreichen und folgt damit dem 1,5‑°C‑Zielpfad.
Die umfassende Zielmatrix sieht vor, die absoluten Scope‑1‑ und Scope‑2‑Emissionen bis 2034 um 58,8% zu senken und die Scope‑3‑Emissionen um 63,8% pro kg Produkt gegenüber dem Basisjahr 2024 zu reduzieren. Langfristig strebt das Unternehmen eine Reduktion von 90% sowohl bei Scope 1 und 2 als auch bei Scope 3 bis 2050 an. WuXi Biologics hat zahlreiche Nachhaltigkeitsauszeichnungen erhalten, darunter das MSCI‑Rating AAA und die EcoVadis‑Platin‑Medaille.
- First-mover advantage as one of the first companies in the industry to receive SBTi approval for climate targets
- Comprehensive ESG excellence demonstrated through multiple prestigious ratings and recognitions
- Clear, measurable environmental targets with specific timeline commitments
- Strong commitment to sustainable supply chain management and stakeholder engagement
- Significant operational changes and investments likely needed to achieve ambitious emissions reduction targets
- Long implementation timeline extending to 2050 for complete net-zero goals
- Potential increased operational costs to meet environmental targets
- Committed to net-zero across the value chain by 2050
- Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation
- Leader in Green CRDMO to drive innovation for a healthier future
WuXi Biologics is one of the first companies in the industry to receive approval for near-term and net-zero targets from SBTi, a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating climate change by setting goals to reduce greenhouse gas (GHG) emissions.
Deeply understanding the importance of tackling climate change, WuXi Biologics has adopted a broad, integrated strategy with measurable targets and a refined roadmap. The company set a GHG emission intensity reduction target in 2021, established an operational net-zero target in 2022, and introduced new, ambitious SBTi targets in 2025. Aligning with 1.5°C pathways to limit global warming, the SBTi target matrix covers Scope 1, 2, and 3 GHG emissions, and includes near-term and net-zero targets.
While diligently pursuing its own climate goals, WuXi Biologics also actively engages with its suppliers through comprehensive sustainable supply chain management to help achieve positive impacts across the entire value chain.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are delighted that our near-term and net-zero GHG targets have been approved by SBTi, an acknowledgement that further inspires our steadfast dedication to tackling climate change and leading the way to a net-zero economy. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to promote responsible practices."
As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score for two consecutive years; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
WuXi Biologics' SBTi Target Matrix
Overall Net-Zero Target
Reach net-zero greenhouse gas emissions across the value chain by 2050.
Near-Term Targets
Reduce absolute scope 1 and 2 GHG emissions
Long-Term Targets
Reduce absolute scope 1 and 2 GHG emissions
About SBTi
The Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis.
It develops standards, tools and guidance which allow companies to set greenhouse gas (GHG) emissions reductions targets in line with what is needed to keep global heating below catastrophic levels and reach net-zero by 2050 at latest.
The SBTi is incorporated as a charity, with a subsidiary which will host its target validation services. Its partners are CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-near-term-and-net-zero-targets-approved-by-sbti-302540905.html
SOURCE WuXi Biologics
FAQ
What are WuXi Biologics' (WXXWY) main environmental targets approved by SBTi?
How does WuXi Biologics plan to achieve its net-zero emissions goals?
What environmental recognitions has WuXi Biologics received?
When did WuXi Biologics start implementing its environmental targets?
What are the long-term environmental targets for WuXi Biologics by 2050?
